BLAINJECTIONINJECTABLE
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
RENFLEXIS (infliximab) by Samsung Bioepis is tumor necrosis factor receptor blocking activity [moa]. Approved for rheumatoid arthritis, crohn's disease, ulcerative colitis and 3 more indications. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENFLEXIS is a biosimilar infliximab (TNF-α receptor blocker) approved in 2017 by Samsung Bioepis. It treats 14 conditions across rheumatology, gastroenterology, dermatology, and rare disease, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. The drug works by blocking tumor necrosis factor, a key inflammatory cytokine driving autoimmune and inflammatory disease.
$0.263MPart D
PeakProduct is in peak lifecycle with modest Part D volume (66 claims, 2023), indicating established market presence but niche positioning as a biosimilar in a competitive TNF-blocker class.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (6)
Worked on RENFLEXIS at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.